undamentalytics Newsletter
Sign in

Lisata Therapeutics, Inc. (LSTA) stock

Add to watchlist

Add holding +

NASDAQ: LSTA Nasdaq Biotechnology Next results ~November 5, 2026

E Fundamentals grade

Lisata Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Lisata Therapeutics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Lisata Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds12 adding, 10 cuttingOf 2 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Lisata Therapeutics files

Where Lisata Therapeutics stands after its latest 10-Q

Lisata Therapeutics has little or no product revenue yet; it used $12m of cash in the twelve months to June 2026. That puts it 115 of 122 for growth among the biotechnology companies we cover. The diluted share count is up 5.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks.

Our model value for Lisata Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Lisata Therapeutics, Inc.'s trailing-twelve-month revenue fell 90.7% year on year, with a free-cash-flow margin of -12323.0%. Where it lags: operating margin of -16427.0% ranks 170 of 175 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -90.7% (-7.7pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 90.7% over the last 12 months.
  • Growth slowing. The growth rate is 7.7 points lower than a quarter earlier.
  • Loss-making. Operating margin is -16427.0%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 14464.4 points on a year ago.
  • Burning cash. Free cash flow was -12323.0% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 1035.0% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.49 against an average estimate of -$0.54: beat by 8.4%
Next report
November 5, 2026

Lisata Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.0%
  • 1 week-4.7%
  • 1 month-31.3%
  • This year-45.7%
  • 1 year-63.8%
  • 5 years-94.3%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$100,000
Operating margin
-16427.0%
Net margin
-14621.0%
EPS (TTM, diluted)
$-1.64

Growth

Revenue growth
−90.7%
Change in growth rate
−7.7 pts
Share count change
+5.1%

Cash

Free cash flow (TTM)
-$12.3M
FCF margin
-12323.0%
Stock pay % of revenue
1035.0%

Earnings

Last results
November 6, 2025

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Leadership
  3. Leadership
  4. Agreement ended
  5. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Lisata Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Lisata Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.72 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.0 ~$0.0–$0.1 Left out: out of range vs price (0.01x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lisata Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162022202320242025Now
Share price$42.45$2.53$2.73$2.98$1.86$1.01
Market value$19m$13m$22m$25m$16m$9m
+ Net debt (− = net cash)$1m−$32m−$23m−$16m−$16m−$10m
Enterprise value$20m−$19m−$553710$9m$201820−$1m
Multiples
Price / sales 0.5x——24.8x95.0x90.0x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

5 /100

Weak moat

How hard Lisata Therapeutics's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -30.2% of total assets over 6 years.

  • Pricing power 0 / 20

    Gross margin has been a median -5.9%, moving by 33019.3 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -1362.5%; its worst year was -321872.8%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 8 years, at a median -909.9% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 1236.1% over five years; stock-based pay has been a median 161.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (10 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.09 +43% — −100%
Next −$1.16 −6% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +6.3% on 90 days ago. In the last 30 days, 0 analysts raised Lisata Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Lisata Therapeutics, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.02 Current fiscal year, 60 days ago: −$0.96 Current fiscal year, 30 days ago: −$0.96 Current fiscal year, 7 days ago: −$0.96 Current fiscal year, Now: −$1.09 −$1.09 Next fiscal year, 90 days ago: −$0.91 Next fiscal year, 60 days ago: −$0.66 Next fiscal year, 30 days ago: −$0.66 Next fiscal year, 7 days ago: −$0.66 Next fiscal year, Now: −$1.16 −$1.16

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.02−$0.91
60 days ago −$0.96−$0.66
30 days ago −$0.96−$0.66
7 days ago −$0.96−$0.66
Now −$1.09−$1.16

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2025 −$0.54 −$0.49 +8.4%
Jun 2025 −$0.65 −$0.54 +16.9%
Mar 2025 −$0.53 −$0.55 −3.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, November 6, 2025

No numeric guidance in Lisata Therapeutics, Inc.'s latest earnings release (filed November 6, 2025). Some companies give their outlook only on the earnings call.

Analyst recommendations

2 analysts, Oct 2026
Buy00%
Hold2100%
Sell00%

Monthly trend

  1. Oct 202622

Counts of recommendations published by analysts covering Lisata Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.3%
of tradable shares
Days to cover
0.11
at average volume
Short interest, 1 month
−83%
to October 15, 2026
Held by institutions
11%
of shares
Held by insiders
20.6%
of shares
Employees
21
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −63.8%

$2.79 on October 31, 2025 to $1.01

ThenNowEffect
Revenue (last 12 months) $1m $100000 −90.7%
P/S multiple 22.1x 90.0x +307.1%
Share count 8m 9m −4.9%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
LSTA−41%−80%+8%+9%−38%−46%
Industry peers (median)−35%−56%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
LSTA25%17%50%50%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
LSTA−71%−85%−56%−32%−52%−80%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 4, 2015 to July 31, 2026. Getting back needed a 20658% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.99 – $5.04
From 52-week high
−80.0%
vs 50-day average
−27.0%
vs 200-day average
−66.2%
Volatility (1 year)
129%
Beta vs S&P 500
0.74

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±5.4%
After a week
5 up, 7 down
typical move ±4.0%
After a month
5 up, 7 down
typical move ±11.5%
Results releasedNext dayS&P 500 next day5 days21 days
November 6, 2025 −12.0% −1.0% −11.5% −16.7%
August 7, 2025 −12.2% +0.7% −13.5% −26.4%
June 17, 2025 −3.2% −0.9% +0.4% +0.8%
May 8, 2025 −8.7% +0.6% +4.3% +14.3%
February 27, 2025 −0.4% −0.1% −2.1% −1.7%
November 12, 2024 −3.8% −0.3% −5.2% −5.9%
August 12, 2024 +0.7% +1.7% +1.4% +9.6%
June 27, 2024 +1.8% −0.2% +2.9% −1.5%
May 9, 2024 +7.3% +0.7% +2.5% +25.5%
February 29, 2024 −1.9% +1.3% −3.2% −1.9%
November 2, 2023 +11.3% +2.8% −0.5% +6.6%
August 14, 2023 −1.1% −0.6% −0.4% −27.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Lisata Therapeutics, Inc. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Lisata Therapeutics, Inc.
$0 $500K $1M $1.5M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $0 Revenue (TTM), FY23 Q4: $0 Revenue (TTM), FY24 Q1: $0 Revenue (TTM), FY24 Q2: $0 Revenue (TTM), FY24 Q3: $0 Revenue (TTM), FY24 Q4: $1M Revenue (TTM), FY25 Q1: $1M Revenue (TTM), FY25 Q2: $1.1M Revenue (TTM), FY25 Q3: $1.1M Revenue (TTM), FY25 Q4: $170K Revenue (TTM), FY26 Q1: $170K Revenue (TTM), FY26 Q2: $100K $100K

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $0
FY23 Q4 $0
FY24 Q1 $0
FY24 Q2 $0
FY24 Q3 $0
FY24 Q4 $1M
FY25 Q1 $1M
FY25 Q2 $1.1M
FY25 Q3 $1.1M
FY25 Q4 $170K
FY26 Q1 $170K
FY26 Q2 $100K
Revenue growth, TTM YoY Lisata Therapeutics, Inc.
-50000% 0% 50000% 100000% FY15 Q1 FY15 Q4 FY16 Q3 FY26 Q2 Revenue growth, TTM YoY, FY15 Q1: 19567.7% Revenue growth, TTM YoY, FY15 Q2: 55311.1% Revenue growth, TTM YoY, FY15 Q3: 89100.0% Revenue growth, TTM YoY, FY15 Q4: 83155.8% Revenue growth, TTM YoY, FY16 Q1: 504.3% Revenue growth, TTM YoY, FY16 Q2: 139.7% Revenue growth, TTM YoY, FY16 Q3: 68.2% Revenue growth, TTM YoY, FY16 Q4: 136.2% Revenue growth, TTM YoY, FY17 Q1: 85.5% Revenue growth, TTM YoY, FY25 Q4: -83.0% Revenue growth, TTM YoY, FY26 Q1: -83.0% Revenue growth, TTM YoY, FY26 Q2: -90.7% -90.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY15 Q1 19567.7%
FY15 Q2 55311.1%
FY15 Q3 89100.0%
FY15 Q4 83155.8%
FY16 Q1 504.3%
FY16 Q2 139.7%
FY16 Q3 68.2%
FY16 Q4 136.2%
FY17 Q1 85.5%
FY25 Q4 -83.0%
FY26 Q1 -83.0%
FY26 Q2 -90.7%
Operating margin (TTM) Lisata Therapeutics, Inc.
-20000% -15000% -10000% -5000% 0% FY16 Q1 FY16 Q4 FY25 Q1 FY26 Q2 Operating margin (TTM), FY16 Q1: -554.9% Operating margin (TTM), FY16 Q2: -408.4% Operating margin (TTM), FY16 Q3: -334.1% Operating margin (TTM), FY16 Q4: -84.2% Operating margin (TTM), FY17 Q1: -70.2% Operating margin (TTM), FY24 Q4: -2240.9% Operating margin (TTM), FY25 Q1: -2165.5% Operating margin (TTM), FY25 Q2: -1962.6% Operating margin (TTM), FY25 Q3: -1876.4% Operating margin (TTM), FY25 Q4: -10710.6% Operating margin (TTM), FY26 Q1: -10178.2% Operating margin (TTM), FY26 Q2: -16427.0% -16427.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY16 Q1 -554.9%
FY16 Q2 -408.4%
FY16 Q3 -334.1%
FY16 Q4 -84.2%
FY17 Q1 -70.2%
FY24 Q4 -2240.9%
FY25 Q1 -2165.5%
FY25 Q2 -1962.6%
FY25 Q3 -1876.4%
FY25 Q4 -10710.6%
FY26 Q1 -10178.2%
FY26 Q2 -16427.0%
FCF margin (TTM) Lisata Therapeutics, Inc.
-15000% -10000% -5000% 0% FY16 Q1 FY16 Q4 FY25 Q1 FY26 Q2 FCF margin (TTM), FY16 Q1: -191.8% FCF margin (TTM), FY16 Q2: -158.9% FCF margin (TTM), FY16 Q3: -122.2% FCF margin (TTM), FY16 Q4: -70.2% FCF margin (TTM), FY17 Q1: -72.4% FCF margin (TTM), FY24 Q4: -1935.6% FCF margin (TTM), FY25 Q1: -1775.9% FCF margin (TTM), FY25 Q2: -1535.7% FCF margin (TTM), FY25 Q3: -1612.7% FCF margin (TTM), FY25 Q4: -9398.2% FCF margin (TTM), FY26 Q1: -8017.6% FCF margin (TTM), FY26 Q2: -12323.0% -12323.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY16 Q1 -191.8%
FY16 Q2 -158.9%
FY16 Q3 -122.2%
FY16 Q4 -70.2%
FY17 Q1 -72.4%
FY24 Q4 -1935.6%
FY25 Q1 -1775.9%
FY25 Q2 -1535.7%
FY25 Q3 -1612.7%
FY25 Q4 -9398.2%
FY26 Q1 -8017.6%
FY26 Q2 -12323.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 70 10 14 15 18 22 35 0 0 1 0 0
Gross profit 20 1 2 2 2 2 4 — — — — —
EBITDA −14 −33 −29 −36 −56 −112 −29 −58 −26 −22 −18 −16
Operating income −19 −34 −30 −37 −58 −114 −30 −58 −26 −22 −18 −16
Net income −23 −47 −54 −39 −55 −81 −33 −54 −21 −20 −17 −15
Diluted EPS −$0.46 −$0.54 −$4.00 −$1.90 −$1.68 −$16.67 −$4.99 −$10.47 −$2.58 −$2.40 −$1.91 −$1.64
Growth (year on year)
Revenue — −85.6% +42.6% +2.4% +22.3% +25.4% +56.9% −100.0% — — −83.0% −90.7%
Margins
Gross margin 28.9% 14.0% 16.6% 11.7% 12.6% 10.4% 11.8% — — — — —
EBITDA margin −19.7% −324.0% −205.1% −244.1% −313.0% −496.9% −82.2% — — <−999% <−999% <−999%
Operating margin −27.0% −338.4% −212.0% −250.9% −321.9% −506.3% −83.6% — — <−999% <−999% <−999%
Net margin −33.4% −469.0% −375.2% −265.7% −305.9% −359.7% −92.6% — — <−999% <−999% <−999%
Free-cash-flow margin −35.6% −214.0% −100.4% −203.1% −281.8% −188.7% −70.2% — — <−999% <−999% <−999%
Cash flow
Cash from operations −8 −21 −14 −27 −47 −39 −24 −21 −20 −19 −16 −12
Capital spending 16 1 1 3 4 3 1 0 0 0 0 0
Free cash flow −25 −22 −14 −30 −51 −42 −25 −21 −20 −19 −16 −12
Stock-based pay — 10 7 7 11 10 3 3 2 2 1 1
Free cash flow after stock pay — −32 −21 −37 −62 −52 −27 −24 −22 −21 −17 −13
Balance sheet
Cash 16 4 14 46 19 19 7 32 23 16 16 10
Total debt 10 0 0 3 16 16 8 0 0 0 0 0
Net debt (negative = net cash) −6 −4 −13 −43 −3 −2 1 −32 −23 −16 −16 −10
Diluted shares — — — — — — — 5m 8m 8m 9m 9m
Returned to shareholders
Dividends 0 0 0 0 0 — — — — — — —
Total returned 0 0 0 0 0 — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $11m
Short-term assets $11mLonger-term assets $0m
What it owes, and who funded it · $11m
Short-term liabilities $3mLonger-term liabilities $0mShareholders' equity $8m
  • Short-term assets cover short-term liabilities $11m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $11m short-term assets against $50,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Lisata Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+5.1%
year over year
R&D spending
4881.0%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated LSTA IBIO AIM CLDX CLNN CRVO Median
Revenue, last 12 months $100000 $100000 $95000 $158000 $197000 $331295 $56m
Revenue growth, last 12 months −90.7% −75.0% −21.5% −97.3% −31.1% −95.7% 12.6%
Revenue growth, 3-year average — −62.4% −17.3% −63.5% −36.9% −52.7% 13.7%
Revenue growth, latest quarter −100.0% −100.0% 4.0% −97.0% 233.3% −100.0% 10.2%
Gross margin 7.7% 59.9% −968.5% — 70.1% 100.0% 82.9%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −189.4%
Operating margin, 3-year average <−999% <−999% <−999% <−999% <−999% <−999% −363.5%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −169.8%
Cash from operations / revenue <−999% <−999% <−999% <−999% <−999% <−999% −168.0%
Free-cash-flow margin <−999% <−999% <−999% <−999% <−999% — −162.4%
Free-cash-flow margin, 3-year average <−999% <−999% <−999% <−999% <−999% — −310.0%
Stock pay / revenue >999% >999% 0.0% >999% >999% 393.0% 20.0%
Change in share count 5.1% 13.9% 49.8% 4.7% 35.4% 8.4% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -90.7% 12.6% 162 of 172
Change in growth rate Growth -7.7pp -0.1pp 110 of 172
Operating margin Profitability -16427.0% -189.4% 170 of 175
Net margin Profitability -14621.0% -157.3% 173 of 180
Free-cash-flow margin Cash generation -12323.0% -145.4% 170 of 176
Stock pay as % of revenue Cash generation 1035.0% 19.2% 172 of 179
Change in share count Balance sheet 5.1% 7.9% 68 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$3.7M
Institutions reporting
30
Shares held vs prior quarter
▲ 4.2%
Positions opened / closed
3 / 6

Top buyers and sellers, Q2 2026: 12 institutions bought and 10 sold ; the biggest buyer was Yakira Capital Management, Inc (+139K shares) and the biggest seller Renaissance Technologies LLC (−132K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $948,046 279K 25.6% ▲ 2.6%
Yakira Capital Management, Inc. $471,107 139K 12.7% New
Css LLC $375,435 110K 10.1% ▲ 78.4%
Deltec Asset Management LLC $282,870 83K 7.6% ▼ 7.6%
Rangeley Capital, LLC $275,400 81K 7.4% ▲ 8.0%
Geode Capital Management, LLC $246,999 73K 6.7% ▲ 2.5%
Virtu Financial LLC $200,000 59K 5.4% ▲ 39.3%
Blackrock, Inc. $186,514 55K 5.0% 0.0%
Vanguard Fiduciary Trust Co $166,478 49K 4.5% ▲ 40.2%
Gts Securities LLC $102,680 30K 2.8% ▼ 3.8%
State Street Corp $86,183 25K 2.3% 0.0%
Jane Street Group, LLC $63,720 19K 1.7% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Lisata Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • November 6, 2025
  • August 7, 2025
  • June 17, 2025
  • May 8, 2025
  • February 27, 2025
  • November 12, 2024

Recent SEC filings

Data status

When each part of this page on Lisata Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Lisata Therapeutics, Inc. in brief

What does Lisata Therapeutics, Inc. do?
Lisata Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Lisata Therapeutics, Inc.'s stock ticker?
Lisata Therapeutics, Inc. trades under the ticker LSTA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Lisata Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Lisata Therapeutics, Inc. reported revenue of $100,000, 90.7% lower than a year earlier, according to its SEC filings.
What is Lisata Therapeutics, Inc.'s free cash flow?
Lisata Therapeutics, Inc.'s free-cash-flow margin is -12323.0% of revenue over the trailing twelve months, ranking 170 of the 176 biotechnology companies we cover.
Who are Lisata Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Yakira Capital Management, Inc. and Css LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Lisata Therapeutics, Inc.'s market cap?
On November 2, 2026, Lisata Therapeutics, Inc.'s market capitalisation was about $9M and net debt of -$10.4M. Market figures come from third-party market data and may be delayed.
Who are Lisata Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Lisata Therapeutics, Inc. are Ibio, Inc., AIM Immunotech Inc., Celldex Therapeutics, Inc., Clene Inc. and Cervomed Inc. The side-by-side comparison below sets their revenue, margins and growth against Lisata Therapeutics, Inc.'s.
When is Lisata Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Lisata Therapeutics, Inc. announces its own schedule.